Skip to main
ALLR

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics is positioned favorably due to the promising clinical performance of stenoparib, which has demonstrated durable benefits and a median overall survival exceeding 25 months in its Phase 2 trial for advanced recurrent ovarian cancer. The company's innovative Drug Response Predictor (DRP) technology enhances patient targeting, potentially leading to improved clinical outcomes and a more efficient drug development process. Additionally, the current valuation reflects a significant upside potential based on net present value (NPV) analyses, indicating a balanced risk-reward scenario for investors.

Bears say

Allarity Therapeutics Inc reported a net loss of $2.8 million, translating to an earnings per share (EPS) of $(0.19), which, while better than some estimates, highlights ongoing financial strain and may indicate limited near-term profitability. The company continues to face significant risks including balance sheet and liquidity challenges, potential failures in clinical trials, and the uncertain ability to gain or maintain necessary regulatory approvals for its products. Additionally, external factors such as competitive pressures, shifting investor sentiment, and evolving healthcare priorities further exacerbate the negative outlook for Allarity Therapeutics's stock.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Dec 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.